|
|
Article: Other News To Note.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
o Aastrom Biosciences Inc., of Ann Arbor, Mich., received notification from Nasdaq that the company is in compliance with all Nasdaq SmallCap listing requirements, including the $1 minimum bid closing price requirement. Aastrom will remain listed on the NasdaqSC exchange. Aastrom is focused on human cell-based therapies.
o Axcan Pharma Inc., of Mont St. Hilaire, Quebec, said the FDA's Gastrointestinal Advisory Committee recommended its Photofrin PDT therapy after examining efficacy and safety findings related to the ablation of high-grade dysplasia associated with Barrett's esophagus. The decision stemmed from the committee's review of clinical data on Photofrin ...